

Document Type		Form
Index Number	I	Registry 130
Version Number	I	1.0
Title	I	Acute Leukaemias
Author	I	Annelot van Amerongen
Authorised By	I	Annelot van Amerongen
Authorised On	I	22-Aug-2023
Release Date:		22-Aug-2023



Treatment Type	🗌 нст 🔲 ст	🗌 IST	Other

Treatment Date ___/ _/ __ (YYYY/MM/DD)

ACUTE LEUKAEMIAS

DISEASE

Note: complete this form only if this diagnosis was the indication for a HCT/CT or if it was specifically requested. Consult the manual for further information.

Date of diagnosis: _ _ _ / _ / _ (YYY/MM/DD)

Classification:

Acute myeloid leukaemia (AML)	
Precursor lymphoid neoplasm (ALL)	
Other acute leukaemia	



Treatment Type	🗌 нст 🔲 ст	🗌 IST	Other
Treatment Date _	//(YY	YY/MM/DE))

Acute Myeloid Leukaemias (AML)

DISEASE	
---------	--

Classification:		
AML with myelodysplasia related changes?		
□ No		
Yes: was there a previous diagnosis of MDS or MDS/MPN?	🗌 No	
	🗌 Yes	(complete MDS or MDS/MPN indication diagnosis form in addition to the current form)
Therapy related myeloid neoplasia (old "secondary acute leukaem	ia")? 🗌] No
Related to prior treatment but not after a previous diagnosis of MDS or MDS/MPN		Yes (complete MDS or MDS/MPN non-indication diagnoses form in addition to the current form)
] Unknown

CHROMOSOME ANALYSIS

Chromosome analysis at diagnosis (all methods including FISH):

Not done or failed		
☐ Yes, abnormal results: Complex karyotype: ☐ No ☐ Yes ☐ Unknown		
Number of abno	ormalities:	
Monosomal kar (≥2 autosomal r 1 autosomal mo least 1 structura	nonosomies or Yes phosomy + at Uhknown	
Yes, normal results		
Unknown		



reatment Type	🗌 нст 🔲 ст	🗌 IST	Other
reatment Date _	// (YY	YY/MM/DE))

CHROMOSOME ANALYSIS continued

Indicate below whether the abnormalities were absent, present or not evaluated.

t(15;17)	🗋 Absent 📋 Present 📋 Not evaluated
t(8;21)	Absent Present Not evaluated
inv(16)/ t(16;16)	🗋 Absent 📋 Present 📋 Not evaluated
11q23 abnormality type, if a 11q23 abnormality is present:	🗌 Absent 📋 Present 📋 Not evaluated
t(9;11)	🗋 Absent 📋 Present 📋 Not evaluated
t(11;19)	🗌 Absent 📋 Present 📋 Not evaluated
t(10;11)	🗋 Absent 📋 Present 📋 Not evaluated
t(6;11)	🗌 Absent 📋 Present 📋 Not evaluated
Other abn(11q23); specify:	🗋 Absent 📋 Present
3q26 (EVI1) abnormality type, if a 3q26 abnormality is present.:	🗋 Absent 📋 Present 📋 Not evaluated
inv(3) / t(3;3)	🗋 Absent 📋 Present 📄 Not evaluated
t(2;3)(p21;q26)	Absent Present Not evaluated
Other (3q26)/EVI1 rearrangement; specify:	Absent Present
t(6;9)	🗋 Absent 📋 Present 📋 Not evaluated
abn 5 type, if an abn 5 is present:	🗋 Absent 📋 Present 📋 Not evaluated
del (5q)	🗌 Absent 📋 Present 📋 Not evaluated
monosomy 5	🗋 Absent 📋 Present 📋 Not evaluated
add(5q)	🗌 Absent 📋 Present 📋 Not evaluated
Other abn(5q); specify:	🗋 Absent 📋 Present
abn 7 type, if an abn 7 is present:	🗌 Absent 🔄 Present 📄 Not evaluated
del(7q)	🗌 Absent 🔄 Present 📄 Not evaluated
monosomy 7	🗌 Absent 🔄 Present 📄 Not evaluated
add(7q)	🗌 Absent 🔄 Present 📄 Not evaluated
Other abn(7q); specify:	🗌 Absent 🔲 Present
-17	🗋 Absent 📋 Present 📋 Not evaluated
abn(17p)	Absent Present Not evaluated
t(1;22)	Absent Present Not evaluated
Trisomy 8	Absent Present Not evaluated
Other; specify:	Absent Present

OR

Transcribe the complete karyotype: _



Treatment Type	П НСТ П О	CT 🔲 IST	Other
Treatment Date _	//	(YYYY/MM/DD)	

MOLECULAR MARKER ANALYSIS

Molecular	marker	analysis	at	diagnosis:
morecului	marker	unarysis	u	ulugilosis.

No
Yes

Unknown

Indicate below whether the markers were absent, present or not evaluated.

AML1-ETO (RUNX1/RUNXT1) Molecular product of t(8;21)	Absent	Present	Not evaluated
CBFB-MYH11 Molecular product of inv(16)(p13.1;q22) or (16;16)(p13.1;q22)	Absent	Present	☐ Not evaluated
PML-RAR α Molecular product of t(15;17)	Absent	Present	☐ Not evaluated
MLL (KMT2A)-rearrangement/mutation:	Absent	Present	☐ Not evaluated
MLLT3(AF9)-MLL Molecular product of t(9;11)(p22;q23)	Absent	Present	☐ Not evaluated
MLL-PTD (partial tandem duplication)	Absent	Present	☐ Not evaluated
MLLT4(AF6)-MLL Molecular product of t(6;11)(q27;q23)	Absent	Present	Not evaluated
ELL-MLL Molecular product of t(11;19)(q23;p13.1)	Absent	Present	☐ Not evaluated
MLLT1(ENL)-MLL Molecular product of t(11;19)(q23;p13.3)	Absent	Present	Not evaluated
MLLT10(AF10)-MLL Molecular product of t(10;11)(p12;q23)	Absent	Present	Not evaluated
Other MLL-rearrangement; specify:	Absent	Present	
DEK-NUP214(CAN) Molecular product of translocation t(6;9)(p23;q34)	Absent	Present	☐ Not evaluated
RPN1-EVI1 Molecular product of inv(3)(q21q26.2) or t(3;3)(q21q26.2)	Absent	Present	☐ Not evaluated
RBM15-MKL1 Molecular product of translocation t(1;22)(p13;q13)	Absent	Present	☐ Not evaluated
NPM1 mutation	Absent	Present	Not evaluated
с-КІТ	Absent	Present	Not evaluated
DNMT3A	Absent	Present	Not evaluated
ASXL1	Absent	Present	Not evaluated
TP53	Absent	Present	Not evaluated
RUNX1	Absent	Present	Not evaluated
IDH2	Absent	Present	Not evaluated
IDH1	Absent	Present	☐ Not evaluated
BRAT	Absent	Present	Not evaluated
SRSF2	Absent	Present	☐ Not evaluated
SF3B1	Absent	Present	Not evaluated
СЕВРА	Absent	Present	Not evaluated
FLT3-ITD (internal tandem duplication)	Absent	Present	Not evaluated
FLT3-TKD	Absent	Present	☐ Not evaluated
Other; specify:			

Index: Registry 130 | Title: Acute Leukaemias | Version: 1.0 | Effective Date: 2023-08-22 | THIS IS AN UNCONTOLLED COPY

Acute_Leukaemias_v1.0



Treatment Type	🗌 нст 🔲 ст	🗌 IST	Other

Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

DISEASE

Other AML classification:

Acute panmyelosis with myelofibrosis
Myeloid sarcoma (granulocytic sarcoma)
Myeloid proliferations related to Down syndrome
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

ificati FAB o

AB classification:	
AML with minimal differentiation (FAB M0)	
AML without maturation (FAB M1)	
AML with maturation (FAB M2)	
Acute promyelocytic leukaemia (FAB M3)	
Acute myelomonocytic leukaemia (FAB M4)	
Acute monoblastic and monocytic leukaemia (FAB M5)	
Acute erythroid leukaemia (FAB M6)	

Acute megakaryoblastic leukaemia (FAB M7)

Involvement at time of diagnosis:

- ☐ Medullary only
- Extra-medullary only
- Unknown

Organs involved at time of diagnosis:

Skin:	🗌 No	🗌 Yes	☐ Not evaluated
CNS:	🗌 No	🗌 Yes	☐ Not evaluated
Testes/Ovary:	🗌 No	🗌 Yes	☐ Not evaluated
Other; specify:	🔲 No	🗌 Yes	



Treatment Type	🗌 нст 🔲 ст	🗌 IST	Other

Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

Precursor Lymphoid Neoplasms (previously ALL)

DISEASE

Classification:
B lymphoblastic leukaemia/lymphoma
T lymphoblastic leukaemia/lymphoma
Other precursor lymphoid neoplasm; specify:

Secondary origin: is this PLN related to prior exposure to therapeutic drugs or radiation?

□ No

Yes: (If not reported yet, complete respective non-indication diagnosis form in addition to the current form)

Due to exposure to:

Chemotherapy / radiotherapy treated disease

Immune suppression

Other; specify _____

Unknown

CHROMOSOME ANALYSIS

Chromosome analysis at diagnosis (all methods including FISH):

□ Not done or failed	
Yes, abnormal results:	Complex karyotype: 🗌 No 📋 Yes 📋 Unknown
	Number of abnormalities:
Yes, normal results	
Unknown	



Treatment Type	🗌 нст 🔲 ст	IST Other
Treatment Date _	// (YY	YY/MM/DD)

CHROMOSOME ANALYSIS continued

Indicate below whether the abnormalities were absent, present or not evaluated.

t(9;22)	Absent	Present	☐ Not evaluated
11q23 abnormalities (fill in only if 11q23 abnormality is present):	Absent	Present	☐ Not evaluated
t(4;11)	Absent	Present	Not evaluated
Other abn(11q23); specify:	Absent	Present	
t(12;21)	Absent	Present	Not evaluated
Hyperdiploidy > 46 chromosomes (fill in only if hyperdiploidy is present):	Absent	Present	Not evaluated
51-67 chromosomes	Absent	Present	Not evaluated
Trisomy; specify extra chromosome:	Absent	Present	☐ Not evaluated
Other hyperdiploid karyotype; number of chromosomes:	Absent	Present	
Hypodiploidy < 46 chromosomes (fill in only if hypodiploidy is present):	Absent	Present	Not evaluated
Low hypodiploid: 32 - 39 chromosomes	Absent	Present	Not evaluated
Near haploid: 24-31 chromosomes	🗌 Absent	Present	☐ Not evaluated
Monosomy; specify:	Absent	Present	Not Evaluated
Other; number of chromosomes:	Absent	Present	
iAMP21 (intrachromosomal amplification of chromosome 21)	Absent	Present	Not evaluated
t(5;14)(q31;q32)	Absent	Present	□ Not evaluated
t(1;19)	Absent	Present	☐ Not evaluated
Trisomy 8	Absent	Present	□ Not Evaluated

OR

Transcribe the complete karyotype: ____



Treatment Type	🗌 нст 🗌 ст	IST Other
Treatment Date _	/ / (YY	YY/MM/DD)

MOLECULAR MARKER ANALYSIS

Molecular	marker	analvsis	at	diagn	osis:
moreounar	marker	analysis	u	anagin	5515.

🗌 No

- 🗌 Yes
- Unknown

Ph-like ALL?

 \square No (complete the table below)

Yes (complete the table on page 9)

□ Not evaluated

Indicate below whether the abnormalities were absent, present or not evaluated.

BCR-ABL Molecular product of t(9;22)(q34;q11.2)	Absent	🗌 Present 🔲 Not evaluated
PML-RAR α Molecular product of t(15;17)	Absent	Present Not evaluated
MLL (KMT2A)-rearrangement/mutation:	Absent	Present Not evaluated
AFF1(AF4)-MLL <i>M</i> Molecular product of t(4;11)(q21;q23)	Absent	Present Not evaluated
MLLT1(ENL)-MLL Molecular product of t(11;19)(q23;p13.3)	Absent	Present Not evaluated
MLLT3(AF9)-MLL Molecular product of t(9;11)(p22;q23)	Absent	Present Not evaluated
Other MLL-rearrangement; specify:	Absent	Present
TEL(ETV6)-AML1(RUNX1) Molecular product of t(12;21)(p13;q22)	Absent	Present Not evaluated
IL3-IGH Molecular product of translocation t(5;14)(q31;q32)	Absent	Present Not evaluated
TCF3-PBX1 Molecular product of translocation (1;19)(q23;p13.3)	Absent	Present Not evaluated
IKZF1 (IKAROS) deletion or mutation	Absent	Present 🔲 Not evaluated
NOTCH1 / FBWX7 mutation	🔲 Absent	Present Not evaluated
PAX5 mutation	Absent	🔲 Present 🔲 Not evaluated
KRAS mutation	Absent	🗌 Present 🔲 Not evaluated
NRAS mutation	Absent	Present 🔲 Not evaluated
PTEN mutation	Absent	🔲 Present 🔲 Not evaluated
FLT3 mutation	Absent	🔲 Present 🔲 Not evaluated
PTPN11 mutation	Absent	Present 🔲 Not evaluated
BCL/MYC-rearranged	Absent	Present 🔲 Not evaluated
Other; specify:	Absent	Present



Treatment Type	🗌 нст 🔲 ст	🗌 IST	Other

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

MOLECULAR MARKER ANALYSIS continued

CRFL2-P2RY8	Absent	Present Not evaluated
Other CRFL2 rearrangement; specify:	Absent	Present
ABL1 rearrangement:	Absent	Present 🔲 Not evaluated
ABL1-ETV6	Absent	Present Not evaluated
ABL1-NUP214	Absent	🗌 Present 🔲 Not evaluated
Other ABL1 rearrangement; specify:	Absent	Present
ABL2 rearrangement:	Absent	Present Not evaluated
ABL2-RCSD1	Absent	Present 🔲 Not evaluated
Other ABL2 rearragement; specify:	Absent	Present
JAK2 rearrangement:	Absent	Present 🔲 Not evaluated
JAK2-PAX5	Absent	Present Not evaluated
JAK2-BCR	Absent	Present Not evaluated
Other JAK2 rearrangement; specify:	Absent	Present
EPOR rearrangement:	🗌 Absent	Present Not evaluated
EPOR-IGH	Absent	Present Not evaluated
Other EPOR rearrangement; specify:	Absent	Present

DISEASE

Involvement at time of diagnosis:

- Medullary only
- Extra-medullary only
- Both, medullary and extra-medullary
- Unknown

Organs involved at time of diagnosis:

Skin:	🗌 No	🗌 Yes
CNS:	🗌 No	🗌 Yes
Testes/Ovary:	🗌 No	🗌 Yes
Other; specify:	No	🗌 Yes

Not evaluated
☐ Not evaluated
☐ Not evaluated



Treatment Type	П нст	🗌 СТ	IST	Other
Treatment Date _	//	(YYY	Y/MM/DD)

Other Acute Leukaemias

DI	SE	ΞA	S	E

Classification:

Acute leukaemias of ambiguous lineage

Acute undifferentiated leukaemia

Mixed phenotype (B, T, NOS)

Natural killer (NK) - cell lymphoblastic leukaemia/lymphoma

Other; specify:

Secondary origin: is this other acute leukaemia related to prior exposure to therapeutic drugs or radiation?

Yes: (If not reported yet, complete respective non-indication diagnosis form in addition to the current form)

Due to exposure to:

Chemotherapy / radiotherapy

☐ Immune suppression

Other; specify _____

Unknown

CHROMOSOME ANALYSIS

Chromosome analysis done before treatment (all methods including FISH):

□ Not done or failed	
Yes, abnormal results:	Complex karyotype: 🗌 No 📄 Yes 📄 Unknown
	Number of abnormalities:
Yes, normal results	
Unknown	

If abnormal:

Transcribe the complete karyotype:



EBMT Centre Identification Code (CIC):	Treatment Type	🗌 нст 🔲 ст	
Hospital Unique Patient Number (UPN):			
Patient Number in EBMT database:	Treatment Date	// (YY)	(Y/MM/DD)

DISEASE

Involvement at time of diagnosis:

- Medullary only
- Extra-medullary only
- ☐ Both, medullary and extra-medullary
- Unknown

Organs involved at time of diagnosis:



Index: Registry 130 | Title: Acute Leukaemias | Version: 1.0 | Effective Date: 2023-08-22 | THIS IS AN UNCONTOLLED COPY

IST Other